Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study

Alzheimer's and Dementia

Volumn 12, Issue 7, 2016, Pages 805-814

  Christian, Bradley T ^a,e   Johnson, Sterling C ^a,c,e   Asthana, Sanjay ^a,a,c   Bendlin, Barbara B ^a,c   Nicholas, Christopher R ^a,c   Oh, Jennifer M ^a,c   Rowley, Howard A ^a,a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^d University of Wisconsin   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Alzheimer's disease; Amyloid imaging; APOE; Cognition; Mild cognitive impairment; Preclinical Alzheimer's disease

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; PITTSBURGH COMPOUND B;

ADULT; ALZHEIMER DISEASE; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED STUDY; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOMETRY; REGISTER; RISK FACTOR; WISCONSIN; AGED; BRAIN; DISEASE EXACERBATION; METABOLISM; NEUROPSYCHOLOGICAL TEST; PROCEDURES; PRODROMAL SYMPTOM; STATISTICS AND NUMERICAL DATA;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PRODROMAL SYMPTOMS; REGISTRIES; WISCONSIN;

EID: 84959233450     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2015.12.009     Document Type: Conference Paper

References (49)

1. [1] Jack, C.R. Jr., Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., et al. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 12 (2013), 207–216.
2. [2] Hardy, J.A., Higgins, G.A., Alzheimer's disease: The amyloid cascade hypothesis. Science 256 (1992), 184–185.
3. [3] Rentz, D.M., Locascio, J.J., Becker, J.A., Moran, E.K., Eng, E., Buckner, R.L., et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 67 (2010), 353–364.
4. [4] Mormino, E.C., Kluth, J.T., Madison, C.M., Rabinovici, G.D., Baker, S.L., Miller, B.L., et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 132 (2009), 1310–1323.
5. [5] Pike, K.E., Savage, G., Villemagne, V.L., Ng, S., Moss, S.A., Maruff, P., et al. Beta-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain 130 (2007), 2837–2844.
6. [6] Rodrigue, K.M., Kennedy, K.M., Devous, M.D. Sr., Rieck, J.R., Hebrank, A.C., Diaz-Arrastia, R., et al. β-Amyloid burden in healthy aging: Regional distribution and cognitive consequences. Neurology 78 (2012), 387–395.
7. [7] Sperling, R.A., Johnson, K.A., Doraiswamy, P.M., Reiman, E.M., Fleisher, A.S., Sabbagh, M.N., et al. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging 34 (2013), 822–831.
8. [8] Hedden, T., Oh, H., Younger, A.P., Patel, T.A., Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology 80 (2013), 1341–1348.
9. [9] Aizenstein, H.J., Nebes, R.D., Saxton, J.A., Price, J.C., Mathis, C.A., Tsopelas, N.D., et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65 (2008), 1509–1517.
10. [10] Marchant, N.L., Reed, B.R., DeCarli, C.S., Madison, C.M., Weiner, M.W., Chui, H.C., et al. Cerebrovascular disease, beta-amyloid, and cognition in aging. Neurobiol Aging 33 (2012), 1006.e25–1006.e36.
11. [11] Storandt, M., Head, D., Fagan, A.M., Holtzman, D.M., Morris, J.C., Toward a multifactorial model of Alzheimer disease. Neurobiol Aging 33 (2012), 2262–2271.
12. [12] Johnson, S.C., Christian, B.T., Okonkwo, O.C., Oh, J.M., Harding, S., Xu, G., et al. Amyloid burden and neural function in people at risk for Alzheimer's disease. Neurobiol Aging 35 (2014), 576–584.
13. [13] Donohue, M.C., Sperling, R.A., Salmon, D.P., Rentz, D.M., Raman, R., Thomas, R.G., et al. The preclinical Alzheimer cognitive composite: Measuring amyloid-related decline. JAMA Neurol 71 (2014), 961–970.
14. [14] Doraiswamy, P.M., Sperling, R.A., Johnson, K., Reiman, E.M., Wong, T.Z., Sabbagh, M.N., et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline: A prospective multicenter study. Mol Psychiatry 19 (2014), 1044–1051.
15. [15] Kawas, C.H., Greenia, D.E., Bullain, S.S., Clark, C.M., Pontecorvo, M.J., Joshi, A.D., et al. Amyloid imaging and cognitive decline in nondemented oldest-old: The 90+ Study. Alzheimers Dement 9 (2013), 199–203.
16. [16] Lim, Y.Y., Pietrzak, R.H., Ellis, K.A., Jaeger, J., Harrington, K., Ashwood, T., et al. Rapid decline in episodic memory in healthy older adults with high amyloid-beta. J Alzheimers Dis 33 (2013), 675–679.
17. [17] Mormino, E.C., Betensky, R.A., Hedden, T., Schultz, A.P., Amariglio, R.E., Rentz, D.M., et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 71 (2014), 1379–1385.
18. [18] Resnick, S.M., Sojkova, J., Zhou, Y., An, Y., Ye, W., Holt, D.P., et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 74 (2010), 807–815.
19. [19] Storandt, M., Mintun, M.A., Head, D., Morris, J.C., Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: Cognitive decline associated with Abeta deposition. Arch Neurol 66 (2009), 1476–1481.
20. [20] Lim, Y.Y., Maruff, P., Pietrzak, R.H., Ames, D., Ellis, K.A., Harrington, K., et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 137 (2014), 221–231.
21. [21] Villemagne, V.L., Pike, K.E., Darby, D., Maruff, P., Savage, G., Ng, S., et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46 (2008), 1688–1697.
22. [22] Kantarci, K., Lowe, V., Przybelski, S.A., Weigand, S.D., Senjem, M.L., Ivnik, R.J., et al. APOE modifies the association between Abeta load and cognition in cognitively normal older adults. Neurology 78 (2012), 232–240.
23. [23] Lim, Y.Y., Ellis, K.A., Ames, D., Darby, D., Harrington, K., Martins, R.N., et al. Abeta amyloid, cognition, and APOE genotype in healthy older adults. Alzheimers Dement 9 (2013), 538–545.
24. [24] Mormino, E.C., Betensky, R.A., Hedden, T., Schultz, A.P., Ward, A., Huijbers, W., et al. Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82 (2014), 1760–1767.
25. [25] Lim, Y.Y., Villemagne, V.L., Pietrzak, R.H., Ames, D., Ellis, K.A., Harrington, K., et al. APOE epsilon4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiol Aging 36 (2015), 1239–1244.
26. [26] Villemagne, V.L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K.A., Salvado, O., et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 12 (2013), 357–367.
27. [27] Sager, M.A., Hermann, B., La Rue, A., Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. J Geriatr Psychiatry Neurol 18 (2005), 245–249.
28. [28] Racine, A.M., Adluru, N., Alexander, A.L., Christian, B.T., Okonkwo, O.C., Oh, J., et al. Associations between white matter microstructure and amyloid burden in preclinical Alzheimer's disease: A multimodal imaging investigation. Neuroimage Clin 4 (2014), 604–614.
29. [29] Sprecher, K.E., Bendlin, B.B., Racine, A.M., Okonkwo, O.C., Christian, B.T., Koscik, R.L., et al. Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. Neurobiol Aging 36 (2015), 2568–2576.
30. [30] Schmidt, M., Rey Auditory Verbal Learning Test: A Handbook. 1996, Western Psychological Services, Los Angeles, California.
31. [31] Wechsler. Wechsler Memory Scale-Revised. 1987, The Psychological Corporation, Harcourt Brace Jovanovich, inc for Psychological Corp, New York.
32. [32] Benedict, R.H., Brief Visuospatial Memory Test—Revised. 1997, Psychological Assessment resources, inc, Odessa, FL.
33. [33] Reitan, R.M., Wolfson, D., The Halstead–Reitan Neuropsychological Test Battery: Therapy and clinical interpretation. 1985, Neuropsychological Press, Tucson, AZ.
34. [34] Trenerry, M.R., Crosson, B., DeBoe, J., Leber, W.R., The Stroop Neuropsychological Screening Test. 1989, Psychological Assessment Resources, Odessa, FL.
35. [35] Wechsler. Wechsler Adult Intelligence Scale—Revised. 1981, The Psychological Corporation, Harcourt brace & co for The Psychological Corporation, San Antonio.
36. [36] Wilkinson, G., The Wide Range Achievement Test: Manual. 3rd ed., 1993, Jastak Association, Wilmington, DE.
37. [37] Clark LR, Koscik RL, Nicholas CR, Okonkwo OC, Engelman CD, Bratzke LC, et al. Mild Cognitive Impairment in the Wisconsin Registry for Alzheimer's Prevention (WRAP) study: Prevalence and characteristics using robust and standard neuropsychological normative data. under review.
38. [38] Koscik, R.L., La Rue, A., Jonaitis, E.M., Okonkwo, O.C., Johnson, S.C., Bendlin, B.B., et al. Emergence of mild cognitive impairment in late middle-aged adults in the Wisconsin Registry for Alzheimer's Prevention. Dement Geriatr Cogn Disord 38 (2014), 16–30.
39. [39] Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 280–292.
40. [40] Rajan, K.B., Wilson, R.S., Weuve, J., Barnes, L.L., Evans, D.A., Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia. Neurology 85 (2015), 898–904.
41. [41] Okonkwo, O.C., Oh, J.M., Koscik, R., Jonaitis, E., Cleary, C.A., Dowling, N.M., et al. Amyloid burden, neuronal function, and cognitive decline in middle-aged adults at risk for Alzheimer's disease. J Int Neuropsychol Soc 20 (2014), 422–433.
42. [42] Villemagne, V.L., Pike, K.E., Chetelat, G., Ellis, K.A., Mulligan, R.S., Bourgeat, P., et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 69 (2011), 181–192.
43. [43] Doherty, B.M., Schultz, S.A., Oh, J.M., Koscik, R.L., Dowling, N.M., Barnhart, T.E., et al. Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. Alzheimer's & dementia: diagnosis, assessment & disease monitoring 1 (2015), 160–169.
44. [44] Resnick, S.M., Bilgel, M., Moghekar, A., An, Y., Cai, Q., Wang, M.C., et al. Changes in Abeta biomarkers and associations with APOE genotype in 2 longitudinal cohorts. Neurobiol Aging 36 (2015), 2333–2339.
45. [45] Ellis, K.A., Lim, Y.Y., Harrington, K., Ames, D., Bush, A.I., Darby, D., et al. Decline in cognitive function over 18 months in healthy older adults with high amyloid-beta. J Alzheimers Dis 34 (2013), 861–871.
46. [46] Thai, C., Lim, Y.Y., Villemagne, V.L., Laws, S.M., Ames, D., Ellis, K.A., et al. Amyloid-related memory decline in preclinical Alzheimer's disease is dependent on APOE epsilon4 and is detectable over 18-months. PLoS One, 10, 2015, e0139082.
47. [47] Liu, C.C., Kanekiyo, T., Xu, H., Bu, G., Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol 9 (2013), 106–118.
48. [48] Wolf, A.B., Valla, J., Bu, G., Kim, J., LaDu, M.J., Reiman, E.M., et al. Apolipoprotein E as a beta-amyloid-independent factor in Alzheimer's disease. Alzheimers Res Ther, 5, 2013, 38.
49. [49] Vos, S.J., Verhey, F., Frolich, L., Kornhuber, J., Wiltfang, J., Maier, W., et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain 138 (2015), 1327–1338.